How Curex GLP-1 works, what it costs, and what the fine print changes
This review isolates Curex's GLP-1 program from its much larger allergy and eczema business. Allergy tests, allergy drops, nasal sprays, and immunotherapy are not counted as AllyRx therapies and do not contribute to the options score.
Curex Inc. states that it does not practice medicine. The GLP-1 terms identify Curex Medical Services P.A., Curex Medical of California P.C., Curex Medical of New Jersey P.C., and affiliates as Curex Medical Group, with licensed providers making clinical decisions. No individual clinician roster is provided on the GLP-1 page.
The program begins with an online medical-history form. A provider reviews the intake and may require either a video visit or asynchronous text consultation based on location and medical history. A requested prescription is never guaranteed, and the service does not replace comprehensive in-person care.
The current page publishes compounded semaglutide injection and ODT from $149 per month and compounded tirzepatide injection and ODT from $199 per month. It says prescription, medication, free shipping, follow-ups, and support are included without a separate membership fee.
The headline amounts are starting prices. The page does not publish every strength, concentration, additive, quantity, higher-dose rate, or renewal total. For that reason, the cards say From rather than Avg., and no exact monthly value is invented beyond the public starting amount.
Older first-party pages list starting-dose tirzepatide injection at $249 and add $100 per month for higher doses. They also describe higher-dose semaglutide surcharges. Newer city pages mention a separate $9.99 program start. None of those terms is reconciled on the current main page.
Orally dissolving tablets are separate dosage forms, not interchangeable labels for injection. The site does not disclose the exact salt form, additives, tablet strength, quantity, pharmacy, or clinical evidence for these compounded ODT products, so both remain unmapped and comparison-disabled.
Curex says its providers may also consider metformin, vitamin B12, or medication for side effects. These are conditional adjuncts without a stable product, route, dose, price, or universal availability. They stay in editorial context rather than adding therapy cards.
The main GLP-1 FAQ excludes Alaska, Arkansas, Connecticut, Hawaii, Massachusetts, New Mexico, and Missouri. A dedicated tirzepatide page excludes the same list except Alaska. The review does not collapse these statements into a national-access claim.
The pharmacy terms refer only to a Curex Pharmacy Network and say patients may select a partner pharmacy. Curex marketing refers to state-licensed pharmacies and third-party testing, but the GLP-1 page does not name the dispensing facility or publish its license, registration category, inspection record, or patient-specific label.
The page says medication is in stock and ships in one to two business days, while also promising free direct-to-door delivery. That is a stated shipping target, not a guaranteed arrival time. Prescribing, payment verification, fulfillment, carrier performance, temperature handling, and state rules can affect timing.
Subscriptions renew automatically until cancelled by calling or emailing Curex. Monthly plans can be cancelled or paused only before the next order enters fulfillment. Once compounding, preparation, or shipment starts, the full cost is owed and no partial-period credit is promised.
Prepaid plans remain active through the paid term without prorated refunds. Customized medicines cannot be returned, signup fees are non-refundable, and a completed clinical consultation can account for a non-refundable service fee of up to $100 even when no medication ships.
A broad weight-loss warranty appears in Curex's general terms, but eligibility requires a continuous 16-week course, no other weight-loss prescription in the prior 12 months, every check-in, portal weight logs, proof of starting and ending weight, and a timely claim. The document says approved refunds cover program membership fees, even though the GLP-1 page advertises no membership fee. That conflict prevents presenting the warranty as a simple money-back promise.
Curex clearly discloses that compounded medications are not FDA approved. Elsewhere it refers to testing through FDA and DEA certified labs. FDA says it does not approve or license compounding pharmacies or outsourcing facilities and warns telehealth companies against implying such approval. The review therefore treats the testing phrase as unverified marketing rather than a regulatory credential.
FDA also distinguishes compounded products from approved generics and says it does not review compounded drugs before marketing for safety, effectiveness, or quality. Curex's ODT products and injectable compounds must be evaluated by their patient-specific prescriptions and labels, not assumed equivalent to approved semaglutide or tirzepatide brands.
The privacy policy describes collection of identity, billing, health, device, and usage information, sharing with service providers, affiliates, clinicians, and pharmacies, and behavioral-advertising choices. The separate privacy notice governs Curex Medical Group's protected health information.
The stored affiliate opportunity is a managed Awin enrollment request reported at $45 per approved sale. The advertiser ID, cookie window, paid-media rules, approval, tracking URL, and customer offer remain pending. The CTA therefore points to the ordinary official page with no promotion claim.
- Curex's allergy-care catalog is excluded; this review covers only the separate GLP-1 service.
- Four real ingredient-and-route cards replace branded or conditional treatment labels.
- Current card headlines are compact from-prices, not fabricated plan averages.
- Older Curex pages conflict with the current injectable tirzepatide price and mention higher-dose surcharges.
- The main and product pages disagree on whether Alaska is excluded.
- The legal documents name Curex Inc. and three Curex Medical Group entities, but not individual clinicians or pharmacies.
- Auto-renewal and fulfillment cutoffs make cancellation timing important.
- FDA guidance contradicts any implication that a compounded drug, pharmacy, or testing lab is FDA approved or licensed.
- Affiliate economics are documented separately and do not affect the 63/100 rating.
